Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites
Virchows Archiv · 2024-12 · 485 (6) · 1007-1019
DOI: 10.1007/s00428-024-03917-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Virchows Archiv, online erschienen am 09.09.2024. Verfasst von Abbas Agaimy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, E…. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Abdominal Neoplasms, Cyclic AMP Response Element Modulator. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Erlangen.
Abstract (Originalsprache)
With the wide use of RNA sequencing technologies, the family of FET::CREB fusion mesenchymal neoplasms has expanded rapidly to include potentially aggressive neoplasms, not fitting any well established WHO entity. Recently, a group of intra-abdominal FET ( EWSR1/FUS ) ::CREB ( CREM/ATF1 ) fused unclassified neoplasms has been reported followed by recent recognition of an analogous extra-abdominal category of unclassified neoplasms carrying EWSR1::ATF1 fusions. We describe 9 additional tumors (5 extra-abdominal and 4 abdominal) carrying an EWSR1::CREM ( n = 8) and FUS::CREM ( n = 1) fusion. Patients were 7 females and 2 males aged 10 to 75 years (median, 34). Extra-abdominal tumors originated in the head and neck (2 sinonasal, 1 orbital) and soft tissues (1 gluteal, 1 inguinal). Abdominal tumors involved stomach (2), mesentery (1), and kidney (1). Tumor size ranged from 3.5 to 11 cm (median, 6). Treatment was radical surgery with (5) or without (2) neo/adjuvant radio/chemotherapy. Extended follow-up of 5 patients (21–52 months; median, 24) showed an aggressive course in two (40%); one died of disseminated metastases 52 months after several intensified chemotherapy regimens, and one was alive with progressive abdominal disease at 21 months. The immunophenotype of the two subcohorts was significantly overlapping with variable expression of EMA (7 of 8), keratin AE1/AE3 (5 of 9), CD99 (4 of 7), MUC4 (2 of 8), ALK (3 of 8), synaptophysin (3 of 9), chromogranin (1 of 8), CD34 (3 of 6), CD30 (1 of 6), PAX8 (1 of 7), and inhibin (1 of 7), but no reactivity with desmin (0 of 8), S100 (0 of 8), and SOX10 (0 of 8). This series further solidifies the notion that FET::CREB fusions are not limited to the triad of angiomatoid fibrous histiocytoma, clear cell sarcoma, and malignant gastrointestinal neuroectodermal tumor, but characterize an emerging family of potentially aggressive neoplasms occurring at both intra- and extra-abdominal sites. These tumors underscore the promiscuity of the FET::CREB fusions and highlight the pivotal role of phenotype-oriented classification of these neoplasms that share the same genotype, still featuring significant biological and behavioral distinctness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany. abbas.agaimy@uk-erlangen.de.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. abbas.agaimy@uk-erlangen.de.
- Department of Pathology, Kaiser Santa Clara, Santa Clara, CA, 95051, USA.
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Förderung
- Universitätsklinikum Erlangen
Zitieren
APA
Agaimy, A., Blakely, M., Breimer, G. E., Hölsken, A., Koppes, S. A., Meidenbauer, N., Rijken, J. A., Schad, A., Simon, A. G., Stoehr, R., Bishop, J. A., & Din, N. U. (2024). Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites. Virchows Archiv, 485(6), 1007-1019. https://doi.org/10.1007/s00428-024-03917-2
Vancouver
Agaimy A, Blakely M, Breimer GE, Hölsken A, Koppes SA, Meidenbauer N, et al. Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites. Virchows Archiv. 2024;485(6):1007-1019. doi:10.1007/s00428-024-03917-2
BibTeX
@article{Agaimy2024,
author = {Agaimy, Abbas and Blakely, Morgan and Breimer, Gerben E and Hölsken, Annett and Koppes, Sjors A and Meidenbauer, Norbert and Rijken, Johannes A and Schad, Arno and Simon, Adrian G and Stoehr, Robert and Bishop, Justin A and Din, Nasir Ud},
title = {Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites},
journal = {Virchows Archiv},
year = {2024},
volume = {485},
number = {6},
pages = {1007--1019},
doi = {10.1007/s00428-024-03917-2}
}
EUVIMED